Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement.

Olfson M, He JP, Merikangas KR.

J Am Acad Child Adolesc Psychiatry. 2013 Apr;52(4):378-88. doi: 10.1016/j.jaac.2012.12.006. Epub 2013 Mar 7.

2.

Psychotropic medication use among adolescents: United States, 2005-2010.

Jonas BS, Gu Q, Albertorio-Diaz JR.

NCHS Data Brief. 2013 Dec;(135):1-8.

3.

Medication use in US youth with mental disorders.

Merikangas KR, He JP, Rapoport J, Vitiello B, Olfson M.

JAMA Pediatr. 2013 Feb;167(2):141-8. doi: 10.1001/jamapediatrics.2013.431.

PMID:
23403911
4.

[Prevalence of psychiatric disorders in French general practice using the patient health questionnaire: comparison with GP case-recognition and psychotropic medication prescription].

Norton J, de Roquefeuil G, David M, Boulenger JP, Ritchie K, Mann A.

Encephale. 2009 Dec;35(6):560-9. doi: 10.1016/j.encep.2008.06.018. Epub . French.

PMID:
20004287
5.

[Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey].

Grolleau A, Cougnard A, Bégaud B, Verdoux H.

Encephale. 2008 Sep;34(4):352-9. doi: 10.1016/j.encep.2007.07.011. Epub 2007 Dec 26. French.

PMID:
18922237
6.

Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement.

McLaughlin KA, Green JG, Hwang I, Sampson NA, Zaslavsky AM, Kessler RC.

Arch Gen Psychiatry. 2012 Nov;69(11):1131-9.

7.

Severity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement.

Kessler RC, Avenevoli S, Costello J, Green JG, Gruber MJ, McLaughlin KA, Petukhova M, Sampson NA, Zaslavsky AM, Merikangas KR.

Arch Gen Psychiatry. 2012 Apr;69(4):381-9. doi: 10.1001/archgenpsychiatry.2011.1603.

8.

Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.

Pullen SJ, Wall CA, Angstman ER, Munitz GE, Kotagal S.

J Clin Sleep Med. 2011 Dec 15;7(6):587-96. doi: 10.5664/jcsm.1456.

9.

Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.

Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):260-8. doi: 10.1089/cap.2013.0107. Epub 2014 May 19.

PMID:
24839998
10.

National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.

Comer JS, Olfson M, Mojtabai R.

J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1001-10. doi: 10.1016/j.jaac.2010.07.007. Epub 2010 Sep 1.

11.

[Psychotropic drug use and mental psychiatric disorders in France; results of the general population ESEMeD/MHEDEA 2000 epidemiological study].

Gasquet I, Nègre-Pagès L, Fourrier A, Nachbaur G, El-Hasnaoui A, Kovess V, Lépine JP.

Encephale. 2005 Mar-Apr;31(2):195-206. French.

PMID:
15959446
12.

Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A).

Merikangas KR, He JP, Burstein M, Swendsen J, Avenevoli S, Case B, Georgiades K, Heaton L, Swanson S, Olfson M.

J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):32-45. doi: 10.1016/j.jaac.2010.10.006. Epub 2010 Dec 3.

13.

Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement.

Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, He JP, Koretz D, McLaughlin KA, Petukhova M, Sampson NA, Zaslavsky AM, Merikangas KR.

Arch Gen Psychiatry. 2012 Apr;69(4):372-80. doi: 10.1001/archgenpsychiatry.2011.160. Epub 2011 Dec 5.

14.

Psychotropic medication use in Canada.

Beck CA, Williams JV, Wang JL, Kassam A, El-Guebaly N, Currie SR, Maxwell CJ, Patten SB.

Can J Psychiatry. 2005 Sep;50(10):605-13.

PMID:
16276851
15.

Psychotropic medication use in children and adolescents in an inpatient setting.

Pejovic-Milovancevic M, Miletic V, Popovic-Deusic S, Draganic-Gajic S, Lecic-Tosevski D, Marotic V.

Psychiatriki. 2011 Oct-Dec;22(4):314-9.

PMID:
22271844
16.

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS.

Arch Gen Psychiatry. 1994 Jan;51(1):8-19.

PMID:
8279933
17.

Use of psychotropic medications among HIV-infected patients in the United States.

Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF.

Am J Psychiatry. 2003 Mar;160(3):547-54.

PMID:
12611837
18.

Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication.

Druss BG, Wang PS, Sampson NA, Olfson M, Pincus HA, Wells KB, Kessler RC.

Arch Gen Psychiatry. 2007 Oct;64(10):1196-203.

19.
20.

Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication.

Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC.

Arch Gen Psychiatry. 2005 Jun;62(6):603-13.

PMID:
15939838
Items per page

Supplemental Content

Write to the Help Desk